Clinical Data ASCO26: In vivo oncology approaches continue to show promise Pharmaceutical TechnologyLilly's $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.OncologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026. Oncology Read full story Post navigation Previous: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to comeNext: ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
